Researchers identified being Black and of the female gender as the strongest predictors of late-stage diagnosis.
Healthy People 2030 defines health disparities as “a particular type of health difference that is closely linked with social, economic and/or environmental disadvantage.” Reducing disparities has come into particular focus because of the COVID-19 pandemic and its disproportionate effects.
Shaakir Hasan, DO, and his colleagues recently conducted a study that evaluated social disparities in the diagnosis and management of bladder cancer using the National Cancer Database to stratify cases of urothelial carcinoma by the National Comprehensive Cancer Network guidelines. They presented their results as the American Society of Clinical Oncology’s 2021 Genitourinary Cancers Symposium. There were 331,714 (76.3%) early, 72,154 (16.6%) muscle invasive, 15,579 (3.6%) locally advanced, and 15,161 (3.5%) metastatic cases identified. The study revealed that the two strongest predictors of diagnosis made at later stages were being Black and of the female gender
Additionally, Black patients and individuals of the female gender also had reduced survival rates. Other factors that predicted later diagnosis included older age, Medicaid insurance and residing in lower-income/less educated/ more rural areas. It is critical to take an interdisciplinary team approach to managing patients with urothelial cancer that includes physicians, nurses, pharmacists, and social workers. This approach should be integrated with a patient-centered model of care that involves shared decision-making to ensure that individuals are empowered to be involved in their disease management.
The Institute of Medicine (IOM) evaluated the differences in the types and quality of healthcare received by U.S. racial and ethnic minorities and nonminorities. The IOM report revealed that there are racial and ethnic disparities in healthcare, and they are associated with worse health outcomes. It is important to eliminate these disparities through an interdisciplinary approach that involves increasing awareness among the public, healthcare providers and other key stakeholders.
Other recommendations include promoting consistent and equitable care using evidence-based clinical practice guidelines, structure payment systems to ensure there is an adequate supply of services to minority patients, support the use of interpretation services, and implement patient education programs to enhance knowledge of how to access care and participate in treatment decisions.
Meet the Board: Otis Brawley Talks Health, Racial Disparities, Cancer Screenings and More
September 30th 2020This episode of Tuning Into The C-Suite welcomes our first of many episodes part of the new “Meet the Board” podcast series. Listeners will now hear from a member of Managed Healthcare Executive's Editorial Advisory Board once a month at the end of each month. The first guest featured is Physician and former Executive VP of the American Cancer Society, Otis Brawley. Brawley is a Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.
Listen
3 Upcoming Urothelial Cancer Conferences
August 12th 2021At this time, two of three conferences have been reverted to a in-person and virtual format. This includes The American Urological Association (AUA) 2021 Annual Meeting and the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.
Read More
Updated SITC Immunotherapy Guidelines for Urothelial Cancer
August 3rd 2021The Society for Immunotherapy of Cancer (SITC) released guidelines based on FDA approved immune checkpoint inhibitors (ICIs) for the treatment of urothelial cancer arising from the bladder and other areas of the urinary tract. The guidelines were based around therapies such as the programmed cell death protein 1 (PD-1) inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab) and the programmed cell death ligand 1 (PD-L1) inhibitors, Tecentriq (atezolizumab), Bavencio (avelumab) and Imfinzi (durvalumab).
Read More
Integrating Advanced Practice Providers into Oncology Settings for Managing Urothelial Cancer
July 6th 2021According to the American Urological Association, 72.5% of urologists used Advanced Practice Providers in their practice and these healthcare providers performed a variety of procedures such as a cystoscopy (procedure examining bladder lining), which assists in the diagnosis of bladder cancer. Evidence shows patients have demonstrated a growing acceptance of APPs in urology practice settings.
Read More